Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19090720 | 1.00 | LMNA (0.48) | LMNAKDM4ETDP1CNR1ADRA1A | |
| SCHEMBL20988048 | 1.00 | LMNA (0.48) | LMNAKDM4ETDP1CNR1ADRA1A | |
| SCHEMBL19091370 | 0.87 | LMNA (0.41) | LMNAKDM4ETDP1CNR1ADRA1A | |
| SCHEMBL14378538 | 0.84 | KDM4E (0.40) | LMNAKDM4ETDP1CNR1ADRA1A | |
| SCHEMBL11001406 | 0.81 | LMNA (0.44) | LMNAKDM4ETDP1CNR1ADRA1A | |
| SCHEMBL20987984 | 0.81 | THRB (0.40) | LMNAKDM4ETDP1CNR1ADRA1A | |
| SCHEMBL27212653 | 0.80 | LMNA (0.44) | LMNAKDM4EMEN1KMT2A | |
| SCHEMBL118048 | 0.80 | LMNA (0.44) | LMNAKDM4EMEN1KMT2A | |
| SCHEMBL26699573 | 0.78 | HPGD (0.41) | LMNAKDM4ETDP1CNR1ADRA1A | |
| SCHEMBL20988022 | 0.77 | LMNA (0.50) | LMNAKDM4ETDP1CNR1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696707-B2 | Polyene macrolide derivative | SHIONOGI & CO., LTD. (JP) | 2020-06-30 | — | — | US | disclosed |
| US-20190135847-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2019-05-09 | — | — | US | disclosed |
| US-7629339-B2 | inhibitors of protein kinases and are useful in treating cancer; 4-({5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carbonyl}-amino)-3-methoxy-butyric acid; anticarcinogenic agent | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135847-A1 | POLYENE MACROLIDE DERIVATIVE | ERG28, RPL23, RPL10 | LMNA 742/4885KDM4E 1641/4885TDP1 4057/4885 |
| US-10696707-B2 | Polyene macrolide derivative | ERG28, RPL23, RPL10 | LMNA 742/4885KDM4E 1641/4885TDP1 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.